Parabilis is teeing up the latest high-profile stock issuance in a year when biotech IPOs are averaging more than $286 ...

Immunovant shares climbed on results an analyst deemed “compelling” in tough-to-treat arthritis. Elsewhere, Wave’s pioneering rare disease program advanced and Takeda lost an antitrust suit.

The collaboration marks an “evolution” in the pharmaceutical giant’s use of AI and adds to a series of broad deals its peers ...

Mentari Therapeutics, a spinout from the prolific hub-and-spoke biotech Paragon, is developing two medications it hopes can ...

Westlake BioPartners headed to Texas for its latest biotechnology venture, launching Oorja Bio with $30 million in Series A funding to make new drugs for cardiopulmonary and fibrotic diseases. The ...

Tested in a condition known as ENPP1 deficiency, the treatment failed a trial goal that’s important to regulators, spurring ...

While early, the findings suggest the therapy could be superior to Novartis’ Vijoice at treating “vascular anomalies,” a ...

A two-drug regimen of Regeneron’s fianlimab and Libtayo didn’t significantly outperform Keytruda in a late-stage study, a ...

The endometrial cancer trial is the first of 17 late-stage studies Merck is running for a therapy that’s important to its ...

Baxfendy inhibits a blood-pressure-raising enzyme and, according to AstraZeneca executives, is poised to be a “big product” ...

The agency has once again shuffled the leadership for two top drug review offices. Elsewhere, Parabilis partnered with Regeneron and an obesity pill is headed toward an approval in China.

Once a drug lost primary patent protection or hit a certain age, it was managed for steady — if declining — cash flow with ...